MIR Q2 Deep Dive: Margin Expansion and Nuclear Backlog Growth Offset Revenue Miss
Mirion (NYSE: MIR) reported Q2 CY2026 revenue of $266.8 million, up 19.7% year over year but slightly below analysts’ $269.6 million estimate. Non-GAAP EPS was $0.12, above the $0.10 consensus, and adjusted EBITDA was $65.3 million. Management reiterated full-year Adjusted EPS guidance of $0.52 and EBITDA guidance of $292.5 million at the midpoint, citing margin expansion and nuclear backlog growth.
How this was made
The 30-second read
Why it matters
Traders can reassess the probability-weighted path for second-half revenue conversion and margin expansion given the reiterated full-year midpoint guidance and the stated drivers (nuclear backlog growth, medical hardware delays, AI/product launches).
Market read
A small revenue miss is offset by EPS and EBITDA beats and reiterated guidance, with nuclear backlog growth and margin expansion as the core bull case.
What to watch
Backlog quality and the pace of new-build project conversions are flagged as potential variability; the China cancellation, while called rare, could be an early signal of execution risk.
Background
The article frames Mirion’s Q2 as a margin and backlog story, with revenue slightly below consensus due to segment timing differences.
Ticker impact
Mirion reported Q2 revenue of $266.8M, a 1% miss vs $269.6M estimates, while adjusted EPS and EBITDA beat and guidance was reiterated.
Near-term downside risk from the revenue miss may fade if investors focus on margin expansion and backlog conversion visibility.
The article provides concrete beats (Adj EPS $0.12 vs $0.10, Adj EBITDA $65.3M vs $62.78M) and unchanged midpoint guidance (Adj EPS $0.52, EBITDA $292.5M), but notes the market reaction was negative due to revenue coming in below expectations.
Market effects
Signals continued demand strength in nuclear power and SMR backlog, with medical hardware timing as the main swing factor for radiation safety peers.
China contract cancellation ($18M) highlights geopolitical/project-delay risk in new-build demand, though management frames it as immaterial to long-term guidance.
Backlog visibility (81% of full-year revenue covered) may influence investor confidence in nuclear-adjacent instrumentation and services demand durability globally.
Counterpoint
The revenue miss plus medical hardware delays could indicate backlog conversion is not as smooth as implied, making the second-half acceleration assumption less certain.
Key entities
- companyMirion
Radiation safety company reporting Q2 CY2026 results, margin expansion, and reiterated full-year Adjusted EPS and EBITDA guidance.
- executiveThomas D. Logan
CEO cited for commentary on EBITDA margin expansion and backlog visibility.
- executiveBrian Schopfer
CFO cited for visibility into the back end of the year and backlog coverage (81% of expected full-year revenue).
